These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 29517552)

  • 1. Validation of SIMPLE Index for Lupus Disease Activity.
    Gandhi N; Arora S; Sengupta M; Sequeira W; Jolly M; Block JA
    J Clin Rheumatol; 2018 Sep; 24(6):313-318. PubMed ID: 29517552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lupus Impact Tracker is responsive to physician and patient assessed changes in systemic lupus erythematosus.
    Giangreco D; Devilliers H; Annapureddy N; Block JA; Jolly M
    Lupus; 2015 Dec; 24(14):1486-91. PubMed ID: 26162686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective Validation of the Lupus Impact Tracker: A Patient-Completed Tool for Clinical Practice to Evaluate the Impact of Systemic Lupus Erythematosus.
    Jolly M; Kosinski M; Garris CP; Oglesby AK
    Arthritis Rheumatol; 2016 Jun; 68(6):1422-31. PubMed ID: 26814452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fatigue is independently associated with disease activity assessed using the Physician Global Assessment but not the SLEDAI in patients with systemic lupus erythematosus.
    Mertz P; Piga M; Chessa E; Amoura Z; Voll RE; Schwarting A; Maurier F; Blaison G; Bonnotte B; Poindron V; Fiehn C; Lorenz HM; Korganow AS; Sibilia J; Martin T; Arnaud L
    RMD Open; 2022 Sep; 8(2):. PubMed ID: 36123013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-cultural validation of a disease-specific patient-reported outcome measure for systemic lupus erythematosus in Canada.
    Bourré-Tessier J; Clarke AE; Mikolaitis-Preuss RA; Kosinski M; Bernatsky S; Block JA; Jolly M
    J Rheumatol; 2013 Aug; 40(8):1327-33. PubMed ID: 23772082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Associations of the Levels of C4d-bearing Reticulocytes and High-avidity Anti-dsDNA Antibodies with Disease Activity in Systemic Lupus Erythematosus.
    Mora C; Medina-Rosas J; Santos AM; Jaimes DA; Arbeláez AM; Romero C; Cortes A; Londono J
    J Rheumatol; 2016 Sep; 43(9):1657-64. PubMed ID: 27134246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pilot study to determine the optimal timing of the Physician Global Assessment (PGA) in patients with systemic lupus erythematosus.
    Aranow C
    Immunol Res; 2015 Dec; 63(1-3):167-9. PubMed ID: 26514813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Indices to assess patients with systemic lupus erythematosus in clinical trials, long-term observational studies, and clinical care.
    Castrejón I; Tani C; Jolly M; Huang A; Mosca M
    Clin Exp Rheumatol; 2014; 32(5 Suppl 85):S-85-95. PubMed ID: 25365095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validity and reliability of retrospective assessment of disease activity and flare in observational cohorts of lupus patients.
    FitzGerald JD; Grossman JM
    Lupus; 1999; 8(8):638-44. PubMed ID: 10568901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using Clinical Characteristics and Patient-Reported Outcome Measures to Categorize Systemic Lupus Erythematosus Subtypes.
    Rogers JL; Eudy AM; Pisetsky D; Criscione-Schreiber LG; Sun K; Doss J; Clowse MEB
    Arthritis Care Res (Hoboken); 2021 Mar; 73(3):386-393. PubMed ID: 31909888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validity and Reliability of Patient Reported Outcomes Measurement Information System Computerized Adaptive Tests in Systemic Lupus Erythematosus.
    Kasturi S; Szymonifka J; Burket JC; Berman JR; Kirou KA; Levine AB; Sammaritano LR; Mandl LA
    J Rheumatol; 2017 Jul; 44(7):1024-1031. PubMed ID: 28412708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross-cultural validation of Lupus Impact Tracker in five European clinical practice settings.
    Schneider M; Mosca M; Pego-Reigosa JM; Gunnarsson I; Maurel F; Garofano A; Perna A; Porcasi R; Devilliers H
    Rheumatology (Oxford); 2017 May; 56(5):818-828. PubMed ID: 28204765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: measures of overall disease activity.
    American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria
    Arthritis Rheum; 2004 Nov; 50(11):3418-26. PubMed ID: 15529383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How should lupus flares be measured? Deconstruction of the safety of estrogen in lupus erythematosus national assessment-systemic lupus erythematosus disease activity index flare index.
    Thanou A; Chakravarty E; James JA; Merrill JT
    Rheumatology (Oxford); 2014 Dec; 53(12):2175-81. PubMed ID: 24729400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The lupus impact tracker is responsive to changes in clinical activity measured by the systemic lupus erythematosus responder index.
    Devilliers H; Bonithon-Kopp C; Jolly M
    Lupus; 2017 Apr; 26(4):396-402. PubMed ID: 27587460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of disease activity on health-related quality of life in systemic lupus erythematosus - a cross-sectional analysis of the Swiss Systemic Lupus Erythematosus Cohort Study (SSCS).
    Chaigne B; Chizzolini C; Perneger T; Trendelenburg M; Huynh-Do U; Dayer E; Stoll T; von Kempis J; Ribi C;
    BMC Immunol; 2017 Mar; 18(1):17. PubMed ID: 28351341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Turkish lupusPRO: cross-cultural validation study for lupus.
    Kaya A; Goker B; Cura ES; Tezcan ME; Tufan A; Mercan R; Bitik B; Haznedaroglu S; Ozturk MA; Mikolaitis-Preuss RA; Block JA; Jolly M
    Clin Rheumatol; 2014 Aug; 33(8):1079-84. PubMed ID: 23934384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of the Cutaneous Lupus Disease Area and Severity Index (CLASI) using physician- and patient-assessed health outcome measures.
    Jolly M; Kazmi N; Mikolaitis RA; Sequeira W; Block JA
    J Am Acad Dermatol; 2013 Apr; 68(4):618-623. PubMed ID: 23107310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Swiss Systemic lupus erythematosus Cohort Study (SSCS) - cross-sectional analysis of clinical characteristics and treatments across different medical disciplines in Switzerland.
    Ribi C; Trendelenburg M; Gayet-Ageron A; Cohen C; Dayer E; Eisenberger U; Hauser T; Hunziker T; Leimgruber A; Lindner G; Koenig K; Otto P; Spertini F; Stoll T; Von Kempis J; Chizzolini C;
    Swiss Med Wkly; 2014; 144():w13990. PubMed ID: 25115978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus.
    Ward MM; Marx AS; Barry NN
    J Rheumatol; 2000 Mar; 27(3):664-70. PubMed ID: 10743805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.